Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecbotamab vedotin in advanced solid tumors
NCT03425279Phase 2Completed
- Sponsor
- BioAtla
- Start
- Feb 2018
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of mecbotamab vedotin in undifferentiated pleomorphic sarcoma (UPS), myxofibrosarcoma (MFS), solid tumor, sponsored by BioAtla. Started Feb 2018; status: completed.
02
Drugs
mecbotamab vedotin
03
Conditions
undifferentiated pleomorphic sarcoma (UPS)myxofibrosarcoma (MFS)solid tumor
Beyond the preview
Go deeper on NCT03425279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425279.